Matrix-Producing Cells in Chronic Kidney Disease: Origin, Regulation, and Activation
- First Online:
- Cite this article as:
- Kramann, R., DiRocco, D.P., Maarouf, O.H. et al. Curr Pathobiol Rep (2013) 1: 301. doi:10.1007/s40139-013-0026-7
- 470 Downloads
Chronic injury to the kidney causes kidney fibrosis with irreversible loss of functional renal parenchyma and leads to the clinical syndromes of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Regardless of the type of initial injury, kidney disease progression follows the same pathophysiologic processes characterized by interstitial fibrosis, capillary rarefaction, and tubular atrophy. Myofibroblasts play a pivotal role in fibrosis by driving excessive extracellular matrix deposition. Targeting these cells in order to prevent the progression of CKD is a promising therapeutic strategy; however, the cellular source of these cells is still controversial. In recent years, a growing amount of evidence points to resident mesenchymal cells such as pericytes and perivascular fibroblasts, which form extensive networks around the renal vasculature, as major contributors to the pool of myofibroblasts in renal fibrogenesis. Identifying the cellular origin of myofibroblasts and the key regulatory pathways that drive myofibroblast proliferation and transdifferentiation as well as capillary rarefaction is the first step to developing novel anti-fibrotic therapeutics to slow or even reverse CKD progression and ultimately to reduce the prevalence of ESRD. This review will summarize recent findings and controversies concerning the cellular source of myofibroblasts and will highlight discoveries defining the key regulatory signaling pathways that drive their expansion and progression in CKD.
KeywordsPericyteMyofibroblastInterstitiumCapillary rarefactionMatrix-producing cellsChronic kidney disease
Chronic kidney disease (CKD) is caused by a wide variety of primary renal diseases but, regardless of the type of initial injury, the stereotyped response of the kidney is characterized by expansion of myofibroblasts and accumulation of extracellular fibrotic matrix. The initial recruitment of myofibroblasts is initially beneficial for the normal repair process after injury; however, in the case of chronic injury, this response is maladaptive, leading to overabundant synthesis of matrix which destroys normal kidney architecture, causing CKD progression and end-stage renal disease (ESRD). Extracellular matrix (ECM) is produced both in the interstitial space between tubules (tubulo-interstitium) and in glomeruli, where it causes glomerulosclerosis. This fibrotic process occurs in parallel with capillary rarefaction, inflammation, and tubular atrophy. In recent years, various epidemiologic studies have brought the connection between acute kidney injury and CKD to ESRD progression to widespread attention [1–3]. Because CKD progression is thought to be primarily driven by a gradual worsening of tubulo-interstitial fibrosis , a therapeutic strategy to inhibit the expansion and synthetic capability of myofibroblasts should hold promise in slowing disease progression. Therefore, understanding the cellular and molecular mechanisms of kidney fibrosis (recently reviewed in [4, 5]) will help to develop novel targeted therapies. In this review, we will discuss the recent literature regarding the cellular source of myofibroblasts and summarize the key cell signaling pathways and pathophysiologic processes that contribute to and regulate myofibroblast expansion culminating in the progression of fibrosis and ESRD.
The Cellular Origin of Matrix Producing Cells
It has been widely accepted that activated fibroblasts called myofibroblasts are the pathologic matrix-producing cells in fibrosis across different organs and tissues. In healthy non-injured kidney, myofibroblasts are virtually absent; however, after injury, they expand in a fashion reminiscent of neoplastic disease, destroying kidney architecture and causing renal failure and ESRD. Myofibroblast cells are characterized by a pronounced rough endoplasmic reticulum and a large nucleolus—reflecting their high synthetic and proliferative capability . They express alpha-smooth muscle actin (α-SMA), which is organized in myofilaments and morphologically described as stress-fibers .
Circulating bone marrow-derived progenitors, as fibrocytes and mesenchymal stem cells, have also been discussed as contributors to kidney myofibroblasts. Whereas bone marrow transplantation work using Collagen-1α1 or Collagen-1α2 reporter chimeras [18, 19] shows that there is no significant contribution of circulating bone marrow-derived cells to the renal myofibroblast pool, a recent publication reports bone marrow cells contributing to as much as 35 % to the renal myofibroblast pool [20∙∙]. Bone marrow transplantation experiments using α-SMA-RFP donors and wild-type recipients resulted in 35 % overlay of RFP with α-SMA immunostaining after UUO [20∙∙]. As bone marrow mesenchymal stromal cells (MSC) express α-SMA, the reader might conclude that these cells are the bone marrow cells that contribute to the renal myofibroblast pool. Despite this intriguing result, it remains unclear whether transplanted MSC engraft and whether the α-SMA-expressing cells after transplantation are indeed MSC. Since no single marker for MSC is currently reported that would allow for proper genetic lineage tracing experiments, the gold standard approach for identifying cell hierarchies, more studies are needed to prove that BM-MSC contribute to the myofibroblast pool in models of fibrotic kidney injury.
The most straighforward and traditional explanation is that local resident mesenchymal cells are the major source of myofibroblasts in kidney fibrosis . It is our opinion that this hypothesis is the most plausible one. In recent years, one particular resident mesenchymal cell has become the focus of fibrosis research, the pericyte or perivascular fibroblast that is abundant throughout the kidney and forms an extensive network around capillaries [17∙, 19, 22∙∙, 23]. We performed genetic lineage analysis using an inducible CreERT2 driven by the FoxD1 locus to genetically label and track interstitial pericytes [17∙]. FoxD1 is expressed in the metanephric mesenchyme from gestational day E11.5, and FoxD1+ cells give rise to pericytes and perivascular fibroblasts, vascular smooth muscle cells, and mesangial cells, but they do not have epithelial or endothelial potential [24, 25]. We demonstrated that, after unilateral ureteral obstruction, these genetically labeled FoxD1+ pericytes and perivascular fibroblasts acquire α-SMA expression and are the major contributor to the myofibroblast pool in fibrosis [17∙, 26]. Pericytes have subsequently also come into the focus of groups interested in scarring of other tissues. Goritz et al. [22∙∙] demonstrated that pericytes become myofibroblasts in spinal cord scarring, and Dulauroy et al. [27∙∙] reported that the majority of myofibroblasts in muscle and dermal fibrogenesis are derived from PDGFRα+ and ADAM12+ pericytes.
Recently, LeBleu et al. [20∙∙] reported that pericytes do not contribute to renal fibrosis. In their study, they performed lineage tracing experiments using NG2-YFP and PDGFRβ-RFP mice showing a significant increase of NG2- and PDGFRβ-expressing cells after unilateral ureteral obstruction [20∙∙]. However, they also generated mice in which viral thymidine kinase is expressed under the control of the NG2 promoter or the PDGFRβ promoter in order to ablate these cells while they are proliferating. They showed that ablation of proliferating NG2- or PDGFRβ-expressing cells after induction of renal fibrosis did not result in a reduction of kidney fibrosis [20∙∙]. As ablation of α-SMA-expressing cells did reduce kidney fibrosis by 50 %, the authors concluded that resident fibroblasts are the major source of kidney myofibroblasts [20∙∙]. Importantly, this study confirms that myofibroblasts derived through EMT do not play an important role in fibrosis. However, it also contradicts other work showing that PDGFRβ+ cells produce ECM and contribute to the renal myofibroblast pool [17∙, 28], and also our own experiments showing that the majority if not all α-SMA-expressing cells co-label with PDGFRβ in murine kidney fibrosis models (data not shown). Part of this confusion arises from how pericytes are defined: PDGFRβ and NG2 are not in fact specific pericyte markers and are expressed by other renal cell-types [29, 30]; PDGFRβ, for example, has been reported to be expressed in the rat kidney-fibroblast cell-line NRK49F , suggesting that resident kidney fibroblasts express PDGFRβ. This raises three important questions: are all Foxd1-derived stromal cells pericytes, or just a subset, and could this explain these discordant results, and also could mosaic expression of the thymidine kinase transgenic allele have influenced the interpretation of the ablation experiments [20∙∙]? Clearly, further studies are needed to better define the cellular source of myofibroblasts in kidney fibrosis, with particular focus on rigorous definition of markers that distinguish interstitial resident fibroblasts, pericytes, perivascular fibroblasts, and bone marrow-derived fibroblasts.
Capillary Rarefaction Triggers Fibrosis Progression
Multiple Signaling Pathways are Involved Myofibroblast Transdifferentiation and Expansion
Research over the last few decades provides strong evidence that multiple signaling pathways are involved in myofibroblast transdifferentiation and expansion. We will focus on recent developments within four pathways: Hedgehog-Gli, transforming growth factor beta (TGF-β), platelet-derived growth factor (PDGF), and Wingless/Int (Wnt). Other important pathways in myofibroblast recruitment and expansion have been described, such as Notch, connective tissue growth factor (CTGF), endothelin, and the renin–angiotensin–aldosterone system, but these are outside the scope of the current review.
Transforming Growth Factor Beta (TGF-β)
TGF-β ligands are ubiquitously secreted proteins that exist in at least three isoforms (called TGFβ1, TGFβ2, and TGFβ3) and actively contribute to the regulation of organ development, tumorigenesis, the immune system, and fibrosis. The action of TGF-β is vital for the induction of fibrosis and its related pathogenetic effects in different organ systems like arthritis , diabetic nephropathy (DN) , idiopathic pulmonary fibrosis , and myocardial fibrosis . TGF-β is secreted by, and can signal to, essentially all cells, with wide-ranging effects . It can regulate the immune system and constrain the proliferation of various cell-types . TGFβ coordinates ECM production where its overexpression causes fibrosis [46, 47]. Cells secrete separate TGFβ homodimer and propeptide-derived homodimers in which both homodimers are non-covalently linked . The latter homodimer prevents TGFβ binding to its receptors, thus it is called a latency-associated peptide (LAP) . Another layer in the cell membrane control of TGFβ signaling is through a latent TGFβ binding protein, which is a microfibril-associated protein that tethers the TGFβ-LAP complex to the ECM  and is critical for its proper placement in the ECM . TGFβ ligands binding to its receptor triggers assembly of a complex whose components include serine/threonine protein kinases . In this receptor complex, type II receptors phosphorylate the type I components, which then propagate the signal by phosphorylating SMAD2 and SMAD3 . These form a complex with SMAD4 which enters the nucleus and recognizes the DNA motif CAGAC (the SMAD-binding element) .
TGFβ can also activate other pathways that are collectively referred to as non-canonical TGFβ signaling, including the MAPK, PI3K, and RHO pathways. TGFβ can induce EMT which has consequences for disease progression in cancer . A Phase I trial with fresolimumab, a human monoclonal antibody that inactivates all forms of transforming growth factor-β (TGF-β), showed promising effectiveness in patients with resistant focal segmental glomerulosclerosis . Eli Lilly is investigating a TGFβ1 ligand-selective blocking antibody, LY2382770, in a Phase II trial for kidney fibrosis in DN. An alternative approach to suppress TGFβ signaling is gene transfer of antagonizing signaling molecules, such as the inhibitory SMAD7. Using this technique, a group of researchers showed that forced expression of SMAD7 inhibits fibrosis in models of diabetic kidney disease . In idiopathic pulmonary fibrosis, the progressive fibrotic reaction is linked to epithelium-dependent fibroblast activation in which TGFβ plays a vital role . Perfinidone, which inhibits TGFβ in vitro, induced improvement in lung function in pooled data from two phase III clinical trials . Renal fibrosis is thought to be driven by TGFβ in which it induces ECM production and ultimately kidney failure [59, 60]. Target blockade of TGFβ pathway by overexpressing smad7 resulted in decreased fibrosis in a UUO model in rats . Topical application of P144, a peptide inhibitor of TGFβ1, reduced skin fibrosis in an established mouse model of scleroderma . Fibrotic diseases induced by TGFβ are complex and show individual genetic predisposition that necessitates investigating surrogate markers of TGFβ activation before initiating treatment that is often systemic . Further investigation is required to understand the therapeutic utility of TGFβ pathway inhibition in fibrotic disease states.
Wingless/Int (Wnt) Signaling
The Wnt/β-catenin signaling pathway is an evolutionarily conserved signaling pathway that regulates a variety of cellular outcomes in development and disease. The roles of Wnt/βcatenin signaling in embryogenesis, adult tissue homeostasis, and stem cell renewal are well known ; however, the consequences of inappropriate Wnt/βcatenin signaling to fibrogenesis are now under intensive investigation. Wnt proteins bind a heterodimeric receptor complex, consisting of a Frizzled (Fz) and an LRP5/6 protein. When Fz/LRP is not engaged, GSK3 (serine/threonine kinase) phosphorylates Axin-bound β-catenin . Axin is a scaffold of the destruction complex, which interacts with the tumor suppressor protein, APC, and regulates the stability of cytoplasmic β-catenin. Consequently, β-catenin is ubiquitinated and directed for prompt destruction by the proteasomes, hindering the activation of β-catenin target genes in the nucleus . Upon activation of the canonical Wnt pathway, a crucial first step in Wnt signal transduction is binding of Axin to the cytoplasmic tail of LRP6 . This causes dismantling of the destruction complex, allowing β-catenin to accumulate in the cytoplasm and then translocate to the nucleus to bind to its target genes . Cutaneous wound healing studies in mice reveal that β-catenin signaling is activated as a consequence of injury . In another study, non-restricted activation of β-catenin using a stabilized mutant that resists degradation was sufficient to induce excessive collagen synthesis, mimicking aggressive fibromatoses in humans . In a mouse model of Duchenne muscular dystrophy, loss of dystrophin leads to upregulation of Wnt activity in the serum, which then promotes expansion of Sca1+ stromal cells and leads to skeletal muscle fibrosis . In both systemic sclerosis fibrotic lungs and idiopathic pulmonary fibrosis (IPF), fibroblasts express less secreted frizzled-related protein (SFRP1) when compared with controls .
SFRPs structurally mimic Wnt frizzled receptors and can prevent β-catenin signaling by acting as Wnt decoy receptors . Many studies have identified Wnt pathway inhibitors for potential therapeutic use. ICG-001 interacts with cyclic AMP response element binding (CREB)-binding protein and specifically blocks the β-catenin activation . In lung fibrosis, ICG-001 reduced the fibrotic phenotype after tracheal bleomycin instillation . Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and remodeling in a coronary artery ligation model of myocardial infarction . In mouse models of kidney fibrosis, many wnt genes are upregulated and the canonical Wnt/β-catenin pathway is activated [76–78]. Inhibiting the Wnt pathway by gene delivery of DKK1 attenuates renal fibrosis and inhibits myofibroblast activation in a model of obstructive nephropathy . The Liu group has gone on to show that targeted inhibition of the Wnt pathway by IG-001 hindered progression of interstitial fibrosis in UUO, providing a clear translational strategy for treatment of CKD . Our laboratory has shown that exogenous Wnt4 drives myofibroblast differentiation of a pericyte-like cell line . We produced a mouse model with targeted activation of canonical Wnt/β-catenin signaling in interstitial pericytes and fibroblasts. Spontaneous myofibroblast differentiation in the absence of injury was observed in their kidneys . Conversely, inhibition of Wnt with DKK-1 was shown to inhibit pericyte proliferation, activation, and differentiation independent of canonical β-catenin signaling. The authors suggest that activated LRP-6 closely associates with PDGFR, TGFβR, and CTGF receptors at the cell membrane and Wnts may modulate these signaling pathways to modulate pericyte activity . In rat models of chronic renal allograft failure, both the canonical Wnt and Wnt–Ca2+ pathways were differentially modulated which resulted in increased fibronectin expression and activation of fibroblasts through TGFβ1 . Evidently, more research is needed to understand the pathophysiology of Wnt signaling in fibrosis and define appropriate therapeutic targets.
Platelet-Derived Growth Factor (PDGF) Signaling
The PDGF growth factor system is one of the most well-studied signaling pathways in the kidney (thoroughly reviewed in [82, 83]) and consists of four ligand isoforms (PDGF-A, -B, -C, and -D) and two receptors (PDGFR-α and -β). The entire PDGF system including all four PDGF isoforms and both receptors are upregulated in various models of renal disease including unilateral ureteral obstruction, Thy 1.1 glomerulonephritis, lupus, and ischemia–reperfusion injury . There is strong evidence that the PDGF system is involved in regulation of cell proliferation and migration of myofibroblasts . It has been reported that anti-PDGF-C treatment ameliorates fibrosis in the mouse unilateral ureteral obstruction model , and thast inhibition of PDGF-D prevented renal scarring in a glomerulonephritis model . Chen et al. reported recently that, in kidney fibrosis, all four PDGF isoforms are induced broadly throughout the kidney, with both receptors expressed by pericytes and myofibroblasts. Inhibition of PDGF signaling using an antibody against either receptor PDGFR-α or -β attenuated macrophage infiltration and fibrosis, while using a combination of both anti PDGFR-α and -β antibodies did not show an additional effect . Moreover, treatment with the PDGFR tyrosine kinase inhibitor imatinib did show the same effect with reduced fibrosis and macrophage infiltration . Altogether, there are multiple lines of evidence that the PDGF system represents a viable therapeutic target in renal fibrogenesis.
In 1980, Nusslein-Vollhard et al.  identified Hh performing genetic screens in Drosophila. Since then, work of many groups has reported the involvement of the Hh signaling pathway in development and disease (recently reviewed in ). The Hh family of proteins include three ligands: Sonic hedgehog (Shh), Indian hedgehog (Ihh), and desert hedgehog (Dhh). The Hh ligands act by binding to their membrane receptor Patched (Ptc), thereby releasing a tonic inhibition of Ptc on the transmembrane protein Smoothened (Smo), and activated Smo translocated into the primary cilium accumulates and increases the cilia dwell time of Suppressor-of-fused (SUFU) and the Gli proteins, Gli2 and Gli3 . This process finally leads to the dissociation of the Gli–SUFU complex and the transport of full-length Gli2 and Gli3 into the nucleus, where the transcription of hedgehog target genes, including Gli1 and Ptch1, is induced . Gli proteins are the primary effectors of Hh signaling, and all Gli proteins (Gli1, Gli2, and Gli3) contain an activator domain at their C-terminus, whereas only Gli2 and Gli3 have an N-terminal repressor domain .
Emerging evidence implicates a critical role of the Hh pathway in solid organ fibrosis. There are strong lines of evidence that, in cancer and fibrosis, Hh ligands are secreted by epithelial cells and signal to the surrounding interstitial mesenchymal cells. In carcinogenesis, for example, Hh ligands from cancer cells act on adjacent stromal cells to promote the tumor micro-environment . In liver fibrosis, it has been reported that injured hepatocytes and cholangiocytes secrete Hh ligands, and Hh-responsive hepatic stellate cells undergo transdifferentiation into myofibroblasts and then proliferate . A similar mechanism might exist in lung fibrogenesis with injured epithelial cells secreting Shh signaling to interstitial cells that express the receptor Ptch1 [90, 91].
In renal fibrosis, we, and others, have recently shown that injured tubular-epithelial cells secrete Hh ligands, Ihh and Shh, that signal to Hh-responsive interstitial pericytes/fibroblasts [92, 93]. As several drugs that antagonize the Hh pathway are already in clinical development, primarily as treatment options in cancer , these agents might be promising to treat fibrotic kidney disease. Targeting canonical Hh signaling via inhibition of smoothened with the cyclopamine derivative IPI-926, which has improved half-life and increased potency when compared to cyclopamine, had no effect on the severity of kidney fibrosis in our hands . However, others reported that inhibition of smoothened with cyclopamine reduced kidney fibrosis . The reasons for this remain unclear, and more studies are needed to dissect the role of canonical Hh signaling in renal fibrosis.
However, the cancer literature suggests that non-canonical activation of Gli through alternate pathways such as PDGF, EGF, and TGF signaling might be important . As all of these pathways are activated during renal fibrogenesis, an agent that acts downstream in the Hh pathway directly at the Gli protein might be superior to inhibition of smoothened.
As mentioned, tubulo-interstitial fibrosis is a hallmark of all CKDs, including glomerulopathies. There are a variety of biological mechanisms underlying the progression of fibrosis and, unfortunately, these mechanisms are incompletely understood, and pose a challenge to targeted drug development for this disease. Overall, few treatment regimens have shown a reduction in tubulo-interstitial fibrosis in human renal disease, and little evidence exists to show that existing treatments can induce regeneration of kidney. Clinical trials in CKD and ESRD patients are difficult and often under-powered [96∙], and it is unclear whether inhibition of fibrosis will effect hard end-points such as mortality (randomized controlled clinical trials that effect mortality in ESRD have been reviewed previously [96∙]). Although not necessarily anti-fibrotic, treatment of CKDs with angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) has shown significant renoprotective effect in randomized clinical trials . In the Benazepril trial, the primary benefits observed were a reduction in protein excretion and a decrease in the percentage of patients with a doubling of serum creatinine or progression to dialysis . Likewise, in the ramipril efficacy in nephropathy trial, the ACE inhibitor ramipril was shown to slow the rate of decline of renal function as measured by GFR, and the patients treated with ramipril had significant decreases in the incidence of ESRD compared to patients receiving placebo and other anti-hypertensive drugs . As noted with other CKD trials testing ACE inhibition, the patients who benefit most are those with more pronounced proteinuria . While it is not known if fibrotic readouts are altered in CKD patients treated with ACE inhibitors or ARBs, there are reports of reductions in fibrosis and regeneration of glomerular tissue in rodent models of kidney disease .
Therapies targeting the renin–angiotensin system are widely accepted for use in CKD; however, therapeutics addressing other cell signaling pathways are currently being developed, although some potentially promising candidates have suffered high-profile failures. For instance, bardoxolone methyl, developed by Reata/Abbot, is an Nrf2 pathway inducer that was shown to have beneficial effects in animal models of acute kidney injury and was tested to treat DN in clinical trials [102, 103]. Preliminary results in the BEAM trial showed that the drug could significantly increase eGFR; however, this was tempered by the observation that bardoxolone also significantly increased albuminuria and adverse events, and produced a trend for increased systolic blood pressure [104∙∙]. A larger pivotal clinical trial (the BEACON trial, NCT01351675) testing bardoxolone in patients with DN was terminated early due to higher rates of mortality and serious adverse events in patients treated with the drug .
Attempts at treating diabetic kidney disease were also made by Fibrogen, with a human monoclonal antibody (mAB) against CTGF. This phase II trial has been terminated (NCT0913393) along with a phase I trial in FSGS (NCTNCT00782561). This anti-CTGF mAB is still being tested in patients with liver fibrosis and idiopathic pulmonary fibrosis. Other current trials for kidney disease include a phase II trial that is currently recruiting patients with DN or glomerulosclerosis in order to test an anti-TGFβ mAB being developed by Lilly, called LY2382770 (NCT01113801). Another class of therapies being developed includes the endothelin receptor antagonists. Endothelin-1 is the primary endothelin and acts by binding to two GPCR receptors called endothelin type A (ETA) and endothelin type B (ETB). In the kidney, ETA activation causes preferential vasoconstriction of the efferent arteriole, while ETB activation increases tubular urine output and sodium excretion. Therefore, selective ETA inhibition is hypothesized to provide a benefit in terms of decreased proteinuria in CKD patients and, indeed, this has been supported in animal studies . The ASCEND trial tested a selective ETA antagonist called avosentan in patients with DN against placebo, and all patients were treated with standard therapy regimens for treatment of DN including ACE inhibitors and ARBs [107∙]. While the avosentan produced a substantial reduction in urine albumin to creatinine ratio (ACR) compared to the control arm, there was also a 40–80 % increase in the rate of death, a 50 % increase in cardiovascular events, and a three times greater risk of congestive heart failure. Due to the increased risk of heart failure and cardiovascular events attributed to fluid overload, the trial was terminated early . It is possible that an ETA antagonist may show a benefit with altered dosing, as the high dose used in this trial may have resulted in ETB antagonism and fluid retention. Adding a diuretic to treatment with an ETA antagonist may also limit serious adverse events, as patients with fluid overload were sensitive to loop diuretics . Additional ETA selective/angiotensin II receptor antagonists are being tested in CKD, e.g., Retrophin is testing RE-021 versus the ARB irbesartan in a phase II trial in patients with FSGS and an ACR of 1.0 g/g (NCT01613118, not yet recruiting). Finally, therapeutics against B cell activating factor, or BAFF, are being tested in other kidney diseases. BAFF is associated with a broad range of B cell-mediated autoimmune disorders, and BAFF inhibitors have been shown to play a role in decreasing B cells and positively affect various diseases [109, 110]. GlaxoSmithKline is running a phase II trial with the anti-BAFF mAB called belimumab in membranous glomerulonephritis and Anthera Pharmaceuticals recently initiated a phase II clinical trial entitled BRIGHT-SC to test their BAFF inhibitor called blisibimod in IgA nephropathy [111–113].
The origin of myofibroblasts remains hotly debated; however, we believe the preponderance of data support resident mesenchymal cells, such as pericytes and perivascular fibroblasts, as the major myofibroblast progenitor pool. Whether some of these cells are actually resident fibroblasts is not yet determined. Defining the core signaling pathways driving myofibroblast transdifferentation, proliferation, and maintenance will guide the search for therapeutics that may halt or reverse fibrotic diseases. While clinical research has proved difficult, and no drug has yet been approved in the U.S. to directly treat fibrosis, continued study of myofibroblast biology will ultimately lead to new effective therapies to halt kidney fibrosis.
This work was supported by NIH DK088923 and an Established Investigator Award of the American Heart Association to Benjamin D. Humphreys, by a fellowship from the Deutsche Forschungsgemeinschaft to Rafael Kramann (KR 4073/1-1), by a research fellowship from the National Kidney Foundation to Derek P. DiRocco (2011-D000691), and by a fellowship from the American Society of Nephrology (Ben J. Lipps Research Fellowship) to Omar H. Maarouf.
Compliance with Ethics Guidelines
Conflict of interest
Rafael Kramann, Derek P. DiRocco, and Omar H. Maarouf declare that they have no conflict of interest. Benjamin D. Humphreys is funded by a Grant from Evotec, with the goal of discovering new therapeutic targets to treat kidney fibrosis.
Human and Animal Rights and Informed Consent
This article does not contain any human studies performed by any of the authors. The animal study was performed after approval by the Harvard University Institutional Animal Care and Use Committees.